# An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.

> **NCT05622370** · PHASE1 · UNKNOWN · sponsor: **Overseas Pharmaceuticals, Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Partial Seizure

## Interventions

- **DRUG:** Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB)
- **DRUG:** Brivaracetam sustained-release tablets 100mg
- **DRUG:** Brivaracetam sustained-release tablets 50mg

## Key facts

- **NCT ID:** NCT05622370
- **Lead sponsor:** Overseas Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-13
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05622370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05622370, "An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05622370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*